BackgroundThe European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing Guidelines on Allergen Immunotherapy (AIT) for Allergic Rhinoconjunctivitis. To inform the development of clinical recommendations, we undertook a systematic review to assess the effectiveness, cost-effectiveness, and safety of AIT in the management of allergic rhinoconjunctivitis. MethodsWe searched nine international biomedical databases for published, in-progress, and unpublished evidence. Studies were independently screened by two reviewers against predefined eligibility criteria and critically appraised using established instruments. Our primary outcomes of interest were symptom, medication, and combined symptom and medication scores. Secondary outcomes of interest included cost-effectiveness and safety. Data were descriptively summarized and then quantitatively synthesized using random-effects meta-analyses. ResultsWe identified 5960 studies of which 160 studies satisfied our eligibility criteria. There was a substantial body of evidence demonstrating significant reductions in standardized mean differences (SMD) of symptom (SMD -0.53, 95% CI -0.63, -0.42), medication (SMD -0.37, 95% CI -0.49, -0.26), and combined symptom and medication (SMD -0.49, 95% CI -0.69, -0.30) scores while on treatment that were robust to prespecified sensitivity analyses. There was in comparison a more modest body of evidence on effectiveness post-discontinuation of AIT, suggesting a benefit in relation to symptom scores. ConclusionsAIT is effective in improving symptom, medication, and combined symptom and medication scores in patients with allergic rhinoconjunctivitis while on treatment, and there is some evidence suggesting that these benefits are maintained in relation to symptom scores after discontinuation of therapy.

Allergen immunotherapy for allergic rhinoconjunctivitis : A systematic review and meta-analysis / S. Dhami, U. Nurmatov, S. Arasi, T. Khan, M. Asaria, H. Zaman, A. Agarwal, G. Netuveli, G. Roberts, O. Pfaar, A. Muraro, I.J. Ansotegui, M. Calderon, C. Cingi, S. Durham, R.G. van Wijk, S. Halken, E. Hamelmann, P. Hellings, L. Jacobsen, E. Knol, D. Larenas-Linnemann, S. Lin, P. Maggina, R. Mösges, H. Oude Elberink, G. Pajno, R. Panwankar, E. Pastorello, M. Penagos, C. Pitsios, G. Rotiroti, F. Timmermans, O. Tsilochristou, E.-. Varga, C. Schmidt-Weber, J. Wilkinson, A. Williams, M. Worm, L. Zhang, A. Sheikh. - In: ALLERGY. - ISSN 0105-4538. - 72:11(2017 Nov), pp. 1597-1631. [10.1111/all.13201]

Allergen immunotherapy for allergic rhinoconjunctivitis : A systematic review and meta-analysis

Pastorello, E.;
2017-11

Abstract

BackgroundThe European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing Guidelines on Allergen Immunotherapy (AIT) for Allergic Rhinoconjunctivitis. To inform the development of clinical recommendations, we undertook a systematic review to assess the effectiveness, cost-effectiveness, and safety of AIT in the management of allergic rhinoconjunctivitis. MethodsWe searched nine international biomedical databases for published, in-progress, and unpublished evidence. Studies were independently screened by two reviewers against predefined eligibility criteria and critically appraised using established instruments. Our primary outcomes of interest were symptom, medication, and combined symptom and medication scores. Secondary outcomes of interest included cost-effectiveness and safety. Data were descriptively summarized and then quantitatively synthesized using random-effects meta-analyses. ResultsWe identified 5960 studies of which 160 studies satisfied our eligibility criteria. There was a substantial body of evidence demonstrating significant reductions in standardized mean differences (SMD) of symptom (SMD -0.53, 95% CI -0.63, -0.42), medication (SMD -0.37, 95% CI -0.49, -0.26), and combined symptom and medication (SMD -0.49, 95% CI -0.69, -0.30) scores while on treatment that were robust to prespecified sensitivity analyses. There was in comparison a more modest body of evidence on effectiveness post-discontinuation of AIT, suggesting a benefit in relation to symptom scores. ConclusionsAIT is effective in improving symptom, medication, and combined symptom and medication scores in patients with allergic rhinoconjunctivitis while on treatment, and there is some evidence suggesting that these benefits are maintained in relation to symptom scores after discontinuation of therapy.
allergen; allergen immunotherapy; allergic rhinoconjunctivitis; subcutaneous; sublingual; Immunology and allergy; Immunology
Settore MED/09 - Medicina Interna
ALLERGY
Article (author)
File in questo prodotto:
File Dimensione Formato  
Dhami_et_al-2017-Allergy.pdf

non disponibili

1.29 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/540629
Citazioni
  • ???jsp.display-item.citation.pmc??? 52
  • Scopus 160
  • ???jsp.display-item.citation.isi??? 147
social impact